-
公开(公告)号:US20240262861A1
公开(公告)日:2024-08-08
申请号:US18567475
申请日:2022-06-07
发明人: Maurice MANDAGO , Ricarda WELZ , Stephan T KIESSIG , Simon GERBER
CPC分类号: C07K1/36 , C12N9/6435 , C12Y304/21007
摘要: The present invention relates to a method for isolating plasminogen from a blood plasma fraction comprising dispersing a precipitate of a blood plasma fraction containing plasminogen in a basic aqueous buffer, separating solid parts thereof and removing at least parts of other proteins, and extracting the plasminogen with an acidic aqueous buffer.
-
公开(公告)号:US11759505B2
公开(公告)日:2023-09-19
申请号:US16491408
申请日:2018-03-09
CPC分类号: A61K38/484 , C12N9/6435 , C12P21/00 , C12Y304/21007
摘要: The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.
-
公开(公告)号:US20220080096A1
公开(公告)日:2022-03-17
申请号:US17425393
申请日:2020-01-23
摘要: Surprisingly, it was found that zeolites can be used to decrease the concentration of inorganic ions, such as calcium ions, from a body fluid, such as plasma, in sufficient way. Such decrease of the concentration of inorganic ions, such as calcium ions, was found to lead to an inhibition of hemostasis including an inhibition of coagulation, especially inhibiting the activation of factor VII and the formation of fibrin.
-
公开(公告)号:US20230381289A1
公开(公告)日:2023-11-30
申请号:US18360612
申请日:2023-07-27
CPC分类号: A61K38/484 , C12N9/6435 , C12P21/00 , C12Y304/21007
摘要: The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.
-
公开(公告)号:US20230146662A1
公开(公告)日:2023-05-11
申请号:US17996831
申请日:2021-04-23
发明人: Stephan T. KIESSIG , Ricarda WELZ , Elena WILLIG
CPC分类号: C12N9/6435 , C12Y304/21007 , A61K38/484 , A61P11/00 , A61K38/48 , A61K38/482 , C12Y304/21068
摘要: The present invention relates to plasminogen for use in a method for treating or preventing lung dysfunction associated with the formation of hyaline membranes in a patient, wherein the patient is preferably further administered with at least one plasminogen activator.
-
公开(公告)号:US20220144924A1
公开(公告)日:2022-05-12
申请号:US17433743
申请日:2020-02-25
IPC分类号: C07K16/12 , A61K39/08 , A61P31/04 , A61K9/00 , C12N9/10 , C12N9/16 , C12N11/00 , G01N33/538 , G01N33/573 , G01N33/50
摘要: The present invention relates to a polypeptide comprising an epitope having a sequence homology of at least 75% to a sequence section of both Clostridium difficile toxin A and B. Moreover, the present invention refers to a vaccine comprising such polypeptide. The invention further relates to an antibody binding to Clostridium difficile toxins A and B and to a method for isolating and/or detecting such antibody and to uses of the polypeptides and antibodies.
-
公开(公告)号:US20220072110A1
公开(公告)日:2022-03-10
申请号:US17422962
申请日:2020-01-24
发明人: Stephan T. KIESSIG , Ricarda WELZ , Hanne Rieke GERDING , Marc MAZUR , Hans Joachim ANDERS , Chongxu SHI , Christoph SCHIMMELPFENNIG , Satish Kumar DEVARAPU
IPC分类号: A61K38/48
摘要: The present invention relates to plasminogen for use in a method for preventing or treating a thrombotic event in a patient, wherein the patient is at risk of developing or is suffering from microthrombi.
-
-
-
-
-
-